Prot #NU 16B08: Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date1/20/171/20/23

Funding

  • Merck Sharp & Dohme Corporation (Prot #NU 16B08)